ロード中...
Barriers and solutions in cross-sector care for metastatic prostate cancer patients in Germany: a qualitative study on radioligand therapy
Abstract Background In December 2022, Pluvicto® (lutetium(177Lu)-vipivotide tetraxetan) received European Medicine Agency approval based on the Phase III VISION study as the first radioligand therapy (RLT) directed against prostate-specific membrane antigen (PSMA) and using Lutetium-177 (177Lu) for...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2025-10-01
|
| シリーズ: | BMC Health Services Research |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s12913-025-13540-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|